株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

エリスロポエチン治療薬の世界市場(製品・用途・地域別):市場規模・シェア・世界の動向・企業プロファイル・需要・考察・分析・調査・レポート・市場機会

Global Erythropoietin Drugs Market (Products, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

発行 Allied Market Research 商品コード 324212
出版日 ページ情報 英文 115 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
エリスロポエチン治療薬の世界市場(製品・用途・地域別):市場規模・シェア・世界の動向・企業プロファイル・需要・考察・分析・調査・レポート・市場機会 Global Erythropoietin Drugs Market (Products, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日: 2015年01月15日 ページ情報: 英文 115 Pages
概要

世界のエリスロポエチン(EPO)治療薬市場は、2014年から2020年間に9.7%のCAGRで推移し、2020年までに119億米ドルに達すると予測されています。

当レポートでは、世界のエリスロポエチン(EPO)治療薬市場における最新動向と将来展望について分析し、市場の全体的構造や競争力、将来の市場動向見通し、主な市場促進・阻害要因や市場機会、および治療薬の製品・用途・地域別の市場構造・動向の分析を提供しており、主要企業のプロファイルを交え、お届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • エリスロポエチン薬の進化
  • エリスロポエチンオメガ・デルタ:剪定R&Dパイプライン薬
  • エリスロポエチン薬の倫理的検討事項
  • 主な調査結果
  • バリューチェーン分析
  • 主要企業のポジショニング
  • 特許製品の製品ポジショニング
  • 神経疾患・創傷治癒におけるEPO薬の治験
  • 上位3社に関する競合インテリジェンス
  • 市場シェア分析
  • 市場ダイナミクス

第4章 世界のエリスロポエチン市場:製品別

  • エポエチンアルファ
  • エポエチンベータ
  • ダーベポエチンアルファ

第5章 世界のエリスロポエチン市場:用途別

  • 貧血(がん・HIV治療)
  • 腎臓疾患(ESRD・透析)
  • その他(神経疾患・創傷治癒)

第6章 世界のエリスロポエチン市場:地域別

  • 北米
    • 主な市場動向
    • 医療費償還・規制
    • 主な成長促進要因と市場機会
    • 市場規模と予測
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ(LAMEA)

第7章 企業プロファイル

  • Amgen Inc.
  • Johnson and Johnson
  • Roche
  • Hospira
  • LG Life Sciences Ltd.
  • Biocon
  • Intas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ranbaxy Laboratories Ltd.
  • Celltrion, Inc

図表一覧

目次
Product Code: PH 1559

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020.

Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen's patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.

Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing. Global EPO drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.

Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.

KEY BENEFITS

  • An in-depth analysis of current research and clinical developments within EPO drugs market is provided with key market dynamic factors that helps in understanding the behavior of market
  • The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on
  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework
  • Comprehensive analysis of all geographic regions are provided that helps in determining the prevailing opportunities in these geographies
  • Key market players within the EPO drugs market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global EPO drugs market

MARKET SEGMENTATION

The global EPO drugs market is segmented based on products, applications and geography.

MARKET BY PRODUCT TYPES

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa

MARKET BY APPLICATIONS

  • Anemia (Cancer and HIV treatment)
  • Kidney Disorders (ESRD and Dialysis)
  • Others (Neural Disease and Wound healing)

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 Key Benefits
  • 1.2 Key Market Segments
  • 1.3 Research Methodology
    • 1.3.1 Primary Research
    • 1.3.2 Secondary Research
    • 1.3.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1 Market beyond what to expect by 2025 ($Million)
    • 2.1.1 Moderate growth scenario
    • 2.1.2 Rapid growth scenario
    • 2.1.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

  • 3.1 Market definition and scope
  • 3.2 Evolution of Erythropoietin drugs
  • 3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
  • 3.4 Ethical considerations of erythropoietin drugs
  • 3.5 Key findings
    • 3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
    • 3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market
  • 3.6 Value Chain Analysis
  • 3.7 Key market player positioning (2014)
  • 3.8 Product positioning for patented products (2014)
  • 3.9 Clinical trials for EPO drug in neural diseases and wound healing
  • 3.10 Competitive Intelligence on top three leaders (Amgen, J&J and Roche)
  • 3.11 Market share analysis, 2013
  • 3.12 Market dynamics
    • 3.12.1 Drivers
      • 3.12.1.1 Increasing number cases: including cancer,HIV, kidney disease and anaemia
      • 3.12.1.2 Growing trends of commercialization for erythropoietin biosimilars
      • 3.12.1.3 Readily available reimbursements and favorable government regulations
      • 3.12.1.4 Increasing level of awareness about the benefits of EPO therapeutics
    • 3.12.2 Restraints
      • 3.12.2.1 Unaffordability of therapeutics
      • 3.12.2.2 Longer duration of treatments
      • 3.12.2.3 Adverse amount of side effects
    • 3.12.3 Opportunities
      • 3.12.3.1 Commercialization of darbepotin alfa biosimilar
      • 3.12.3.2 Achieving Economies of scale across developed region with biosimilar version of EPO

CHAPTER 4 GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS

  • 4.1 Epoetin-alfa
    • 4.1.1 Historical Milestones
    • 4.1.2 Commercial outlook
    • 4.1.3 Approaches of clinical trials
    • 4.1.4 Key market trends
    • 4.1.5 Regulatory and reimbursement scenarios
    • 4.1.6 Key growth factors and opportunities
    • 4.1.7 Market size and forecast
  • 4.2 Epoetin-beta
    • 4.2.1 Historical Milestones
    • 4.2.2 Approaches of clinical trials
    • 4.2.3 Key market trends
    • 4.2.4 Regulatory and reimbursement scenarios
    • 4.2.5 Key growth factors and opportunities
    • 4.2.6 Market size and forecast
  • 4.3 Darbepoetin-alfa
    • 4.3.1 Historical Milestones
    • 4.3.2 Commercial outlook
    • 4.3.3 Approaches of clinical trials
    • 4.3.4 Key market trends
    • 4.3.5 Regulatory and reimbursement scenarios
    • 4.3.6 Key growth factors and opportunities
    • 4.3.7 Market size and forecast

CHAPTER 5 GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS

  • 5.1 Anemia (Cancer and HIV treatment)
  • 5.2 Kidney Disorders (ESRD and Dialysis)
  • 5.3 Others (Neural Disease and Wound healing)

CHAPTER 6 GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY

  • 6.1 North America
    • 6.1.1 Key market trends
    • 6.1.2 Reimbursement and regulations
    • 6.1.3 Key growth factors and opportunities
    • 6.1.4 Market size and forecast
  • 6.2 Europe
    • 6.2.1 Key market trends
    • 6.2.2 Reimbursement and regulations
    • 6.2.3 Key growth factors and opportunities
    • 6.2.4 Market size and forecast
  • 6.3 Asia-Pacific
    • 6.3.1 Key market trends
    • 6.3.2 Reimbursement and regulations
    • 6.3.3 Key growth factors and opportunities
    • 6.3.4 Market size and forecast
  • 6.4 LAMEA
    • 6.4.1 Key market trends
    • 6.4.2 Reimbursement and regulations
    • 6.4.3 Key growth factors and opportunities
    • 6.4.4 Market size and forecast

CHAPTER 7 COMPANY PROFILES

  • 7.1 Amgen Inc.
    • 7.1.1 Overview
    • 7.1.2 Amgen Inc. snapshot
    • 7.1.3 Financial performance
    • 7.1.4 Operating Business Segment
    • 7.1.5 SWOT analysis
  • 7.2 Johnson and Johnson
    • 7.2.1 Company overview
    • 7.2.2 Johnson & Johnson snapshot
    • 7.2.3 Operating Business Segment Overview
    • 7.2.4 Financial performance
    • 7.2.1 SWOT Analysis
  • 7.3 Roche
    • 7.3.1 Company overview
    • 7.3.2 Roche Diagnostics snapshot
    • 7.3.3 Operating Business Segment Overview
    • 7.3.4 Financial performance
    • 7.3.5 SWOT analysis of Roche Diagnostics
  • 7.4 Hospira
    • 7.4.1 Company overview
    • 7.4.2 Hospira snapshot
    • 7.4.3 Operating Business Segment Overview
    • 7.4.4 Financial performance
    • 7.4.5 SWOT analysis of Hospira
  • 7.5 LG Life Sciences Ltd.
    • 7.5.1 Company overview
    • 7.5.2 LG Life Sciences Ltd. snapshot
    • 7.5.3 Operating Business Segment Overview
    • 7.5.4 Financial performance
    • 7.5.5 SWOT analysis of LG Life Sciences Ltd.
  • 7.6 Biocon
    • 7.6.1 Company overview
    • 7.6.2 Biocon snapshot
    • 7.6.3 Operating Business Segment Overview
    • 7.6.4 Financial performance
    • 7.6.5 SWOT analysis of Biocon
  • 7.7 Intas Pharmaceuticals
    • 7.7.1 Company overview
    • 7.7.2 Intas Pharmaceuticals snapshot
    • 7.7.3 Operating Business Segment Overview
    • 7.7.4 Financial performance
    • 7.7.5 SWOT analysis of Intas Pharmaceuticals
  • 7.8 Teva Pharmaceutical Industries Ltd.
    • 7.8.1 Company overview
    • 7.8.2 Teva Pharmaceutical Industries Ltd. snapshot
    • 7.8.3 Operating Business Segment Overview
    • 7.8.4 Financial performance
    • 7.8.5 SWOT analysis of Teva Pharmaceutical Industries Ltd.
  • 7.9 Ranbaxy Laboratories Ltd.
    • 7.9.1 Company overview
    • 7.9.2 Ranbaxy Laboratories Ltd. snapshot
    • 7.9.3 Operating Business Segment Overview
    • 7.9.4 Financial performance
    • 7.9.5 SWOT analysis of Ranbaxy Laboratories Ltd.
  • 7.10 Celltrion, Inc
    • 7.10.1 Company overview
    • 7.10.2 Celltrion, Inc. snapshot
    • 7.10.3 Operating Business Segment Overview
    • 7.10.4 Financial performance
    • 7.10.5 SWOT analysis of Celltrion, Inc.

List of Tables

  • TABLE 1 GLOBAL ERYTHROPOIETIN MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 2 GLOBAL ERYTHROPOIETIN RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 3 GLOBAL ERYTHROPOIETIN DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 4 ERYTHROPOIETIN DRUGS (COMPANIES, BRAND NAME, AND VARIANTS)
  • TABLE 5 CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
  • TABLE 6 COMPETITIVE INTELLIGENCE ON TOP THREE LEADERS IN ERYTHROPOIETIN MARKET
  • TABLE 7 BIOSIMILAR VERSION OF ERYTHROPOIETIN COMMERCIALIZED AND UNDER DEVELOPMENT
  • TABLE 8 CMS REIMBURSEMENT CODES FOR ERYTHROPOIETIN
  • TABLE 9 ORIGINATOR EPOTIN ALFA PRODUCTS AND THEIR REVENUES IN 2013
  • TABLE 10 BIOSIMILARS OF EPOETIN ALFA: APPROVED OR IN DEVELOPMENT PHASE
  • TABLE 11 CLINICAL TRIALS OF EPOETIN ALFA
  • TABLE 12 CMS POLICY CODES FOR EPOETIN ALFA
  • TABLE 13 EPOTIN BETA PRODUCTS AND THEIR REVENUES (2013)
  • TABLE 14 CLINICAL TRIALS FOR EPOETIN BETA
  • TABLE 15 CMS POLICY CODES FOR EPOETIN BETA
  • TABLE 16 BIOSIMILARS OF DARBEPOETIN ALFA
  • TABLE 17 CLINICAL TRIALS FOR DARBEPOETIN ALFA
  • TABLE 18 CMS POLICY CODES FOR DARBEPOETIN ALFA
  • TABLE 19 GLOBAL CANCER AND HIV INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
  • TABLE 20 DIALYSIS POPULATION GROWTH RATE IN 2013
  • TABLE 21 ESTIMATED (ESRD PATIENT) POPULATION BASE TAKING EPO THERAPY, 2013-2020, (THOUSAND)
  • TABLE 22 GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
  • TABLE 23 GLOBAL NEURAL DISEASES AND WOUND HEALING INDUCED ANEMIA ERYTHROPOIETIN DRUG APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
  • TABLE 24 GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 25 SYNTHETIC ERYTHROPOIETIN MARKETED IN UNITED STATES
  • TABLE 26 REVISED USFDA GUIDELINES FOR THE DOSING OF ERYTHROPOIETIN STIMULATING AGENTS
  • TABLE 27 CMS POLICY DECISIONS FOR THE REIMBURSEMENT OF ERYTHROPOIETIN STIMULATING AGENTS
  • TABLE 28 NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
  • TABLE 29 EMA APPROVED ERYTHROPOIETIN (BIOSIMILARS AND INNOVATOR PRODUCTS) IN EUROPE
  • TABLE 30 EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
  • TABLE 31 BIOSIMILARS MARKETED IN ASIA-PACIFIC
  • TABLE 32 ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
  • TABLE 33 LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013 - 2020 ($MILLION)
  • TABLE 34 AMGEN INC. SNAPSHOT
  • TABLE 35 AMGEN INC. OPERATING BUSINESS SEGMENT
  • TABLE 36 JOHNSON & JOHNSON SNAPSHOT
  • TABLE 37 JOHNSON AND JOHNSON OPERATING SEGEMENTS
  • TABLE 38 ROCHE SNAPSHOT
  • TABLE 39 ROCHE OPERATING SEGEMENTS
  • TABLE 40 HOSPIRA SNAPSHOT
  • TABLE 41 HOSPIRA OPERATING SEGEMENTS
  • TABLE 42 LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
  • TABLE 43 LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
  • TABLE 44 BIOCON SNAPSHOT
  • TABLE 45 BIOCON OPERATING SEGEMENTS
  • TABLE 46 INTAS PHARMACEUTICALS SNAPSHOT
  • TABLE 47 INTAS PHARMACEUTICALS OPERATING SEGEMENTS
  • TABLE 48 TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
  • TABLE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
  • TABLE 50 RANBAXY LABORATORIES LTD. SNAPSHOT
  • TABLE 51 RANBAXY LABORATORIES LTD. OPERATING SEGEMENTS
  • TABLE 52 CELLTRION, INC. SNAPSHOT
  • TABLE 53 CELLTRION, INC. OPERATING SEGEMENTS

List of Figures

  • FIG. 1 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN MODERATE GROWTH SCENARIO
  • FIG. 2 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN RAPID GROWTH SCENARIO
  • FIG. 3 IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN DIMINISHING GROWTH SCENARIO
  • FIG. 4 GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
  • FIG. 5 EVOLUTION OF ERYTHROPOIETIN DRUGS
  • FIG. 6 TOP IMPACTING FACTORS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013-2020)
  • FIG. 7 TOP INVESTMENT POCKETS FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET
  • FIG. 8 ERYTHROPOIETIN (EPO) VALUE CHAIN BY APPLICATION
  • FIG. 9 MARKET PLAYER POSITIONING OF ERYTHROPOIETIN DRUGS MARKET, 2014, (MILLION)
  • FIG. 10 ERYTHROPOIETIN PATENTED PRODUCT POSITIONING (2014)
  • FIG. 11 MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013)
  • FIG. 12 REGIONAL SALES OF NEORECORMON AND MIRCERA IN 2013 ($ MILLION)
  • FIG. 13 FORECAST ADOPTION OF EPO THERAPY BY GEOGRAPHY, 2013-2020 (% RATE)
  • FIG. 14 FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2013)
  • FIG. 15 FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2013)
  • FIG. 16 SWOT ANALYSIS OF AMGEN INC.
  • FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
  • FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
  • FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
  • FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
  • FIG. 21 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
  • FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIG. 23 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
  • FIG. 24 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
  • FIG. 25 SWOT ANALYSIS OF ROCHE
  • FIG. 26 SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
  • FIG. 27 SWOT ANALYSIS OF HOSPIRA
  • FIG. 28 SWOT ANALYSIS OF INTAS PHARMACEUTICALS
  • FIG. 29 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • FIG. 30 SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
  • FIG. 31 SWOT ANALYSIS OF CELLTRION, INC.
Back to Top